The U.S. Food and Drug Administration has authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for 50 years of age and older people and certain immunocompromised individuals.
Previously, the regulator had authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series.
As per the latest data, a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns.
The latest FDA authorization will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalization and death.
The amendments to the emergency use authorizations or EUAs to include a second booster dose were granted to Pfizer Inc. and ModernaTX Inc.
The FDA-authorized Pfizer-BioNTech COVID-19 Vaccine and the FDA-approved Comirnaty, as well as the FDA-authorized Moderna COVID-19 Vaccine and the FDA-approved Spikevax, can be used to provide the authorized booster dose.
The FDA action applies only to the Pfizer-BioNTech and Moderna COVID-19 vaccines. The authorization of a single booster dose for other age groups with these vaccines remains unchanged, the agency noted.
As per the changes, a second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
The agency also approved a second booster dose of the Pfizer-BioNTech COVID-19 Vaccine to be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise.
Further, the FDA also authorized a second booster dose of the Moderna COVID-19 Vaccine to be administered at least 4 months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.
For comments and feedback contact: editorial@rttnews.com
Health News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.